Gamgee Seeks to Turn a Viral Dog-Vaccine Case Into a Business

The story went viral in March. A Sydney tech entrepreneur, Paul Conyngham, said on X that he used ChatGPT and computational genomics to design a personalized mRNA cancer vaccine for his dying dog, Rosie. Several of her tumors shrank.

Five months later, that single uncontrolled case has a company around it. Gamgee, founded by Conyngham, was accepted into Y Combinator's Summer 2026 batch. It is now running clinical trials in Australia while accepting cases globally, Conyngham wrote Tuesday on X. "My dog Rosie was given months to live. Chemo and immunotherapy failed. I used ChatGPT and computational genomics to design a personalized mRNA cancer vaccine for her tumour. Several of her tumours shrank," he posted.

The business model rests on a specific technical claim. Gamgee sequences a dog's tumor and healthy DNA side by side, identifies the mutations driving that individual cancer, and designs an mRNA vaccine that teaches the immune system what to attack, according to the company's site. The company manages the chain from vet intake through genomic analysis, manufacturing, treatment and monitoring, per its Y Combinator profile. Rosie's vaccine, produced with scientists at UNSW's RNA Institute, is believed to be the first fully computationally designed mRNA cancer vaccine ever delivered to a dog, Gamgee says.

The gap between a viral case and a repeatable product is large, and the company's own sources flag it. Rosie's treatment is a single, uncontrolled observation. Mast cell tumors, the type she had, can behave unpredictably even without treatment. "We cannot be sure how much of Rosie's improvement is due to the vaccine, how long it will last, or whether the same approach would help other dogs," veterinary oncologist Justin Stebbing wrote in The Conversation. One of Rosie's tumors resisted the first vaccine entirely, prompting a second round of analysis and a follow-up shot targeting different mutations, Stebbing said.

Ashley Kalinauskas, CEO of Torigen, a veterinary cancer immunotherapy company that has treated roughly 2,000 animals, offered a sharper version of the same caution. "It's super cool, I think that it's going to be a challenge to really understand how that could be applied to your everyday dog patient," Kalinauskas told R&D World. Even a simplified version of what Conyngham did would take months of focused work to reproduce, she said. Key details about Rosie's case, including the tumor's grade, were not made public. That information matters for interpreting the outcome.

Gamgee is not entering an empty field. Personalized mRNA cancer vaccines have been in development for at least a decade in human medicine. Moderna and Merck's mRNA-4157 cut the risk of melanoma recurrence or death by 44% in a randomized trial, Merck said in a 2022 press release.

Veterinary oncology's current personalized treatments include autologous cancer vaccines, built from a patient's own tumor tissue. The American Animal Hospital Association's 2026 oncology guidelines describe that approach as appealing for its individualized nature but still lacking strong peer-reviewed evidence of efficacy. None of those existing methods sequence a tumor's genome and design a vaccine around its specific mutations the way Rosie's did. That is what made her case novel.

That novelty is also Gamgee's central business risk. A viral single case is compelling because it is unusual and hard to verify from the outside. A repeatable clinical product must work the opposite way: producing consistent outcomes across dogs with different tumor types and disease stages, tested against a control rather than against the emotional weight of one story.

Conyngham said on X that Gamgee is actively recruiting veterinary oncologists and trial partners and is seeking funding for a more rigorous study. The statement acknowledges that the evidence supporting the company's core claim does not yet exist in the form regulators, veterinarians or skeptical pet owners will eventually require.